Canadian Manufacturing

Cannabix Technologies and Omega Laboratories Inc. enter partnership to commercialize technology

by CM Staff   

Exporting & Importing Financing Manufacturing Operations Risk & Compliance Sales & Marketing Supply Chain Alcohol & Cannabis cannabis cannabis manufacturing Manufacturing marketing regulations sales


Omega will be the exclusive laboratory in North America to process and analyze Cannabix delta9 THC breath sample cartridges in conjunction with its Breath Collection Unit and Mass Spectrometer Breath Sampler technology for five (5) years.

VANCOUVER — Cannabix Technologies Inc. reports that it has entered into a strategic partnership and development agreement dated May 15, 2024 with Omega Laboratories Inc of Ohio, USA. The Agreement provides a pathway for commercialization of Cannabix’s marijuana breathalyzer technology.

Omega Laboratories is involved in identifying forensic drugs and abuse testing. Omega has multiple federal as well as international certifications and accreditations for its facility and has experience in novel technology for detection of drugs of abuse.

Pursuant to the Agreement, Cannabix and Omega Laboratories have agreed to, among other things, complete research and development, refine and expand the use of Cannabix’s technology to meet existing and emerging needs of Omega’s clients, contemplate manufacturing and distribution and introduce the delta9 THC breath testing technology to customers in North America.

Omega will be the exclusive laboratory in North America to process and analyze Cannabix delta9 THC breath sample cartridges in conjunction with its Breath Collection Unit and Mass Spectrometer Breath Sampler technology for five (5) years.

Advertisement

The Agreement contemplates critical steps to further Cannabix’s technology from the research and development stage to commercialization.

Pursuant to the Agreement, the Parties agreed to key milestones that will provide mutual benefits to each of Cannabix and Omega including validation of results, publication of validation results to industry journals, and enter into potential large-scale studies, and testing agreements with Omega’s clients.

The Agreement contemplates hardware licence fees, revenues, future manufacturing, distribution arrangements, carve outs and leaves the door open for additional agreements in other global jurisdictions.

Bill Corl, CEO of Omega Laboratories, stated, “Our partnership with Cannabix Technologies underscores our commitment to staying at the forefront of advancements in drug testing technology. By incorporating their groundbreaking THC breathalyzer technology, we are poised to enhance the accuracy, efficiency, and accessibility of cannabis testing.”

The Agreement includes an “R&D Phase” and “Commercial Phase” and “Exclusive Testing” of Cannabix’s delta9 THC breath sample cartridges for drugs for five (5) years within North America, subject to certain exemptions as set out in the Agreement. The R&D phase covers key milestone developments where the Parties will work within Omega’s certified laboratories. During the Commercial Phase of the Agreement, the Parties will determine, pricing, licensing and other revenue parameters.

Manufacturing, Distribution, Intellectual Property and Other Terms

  • During the Commercial Phase, the Parties have agreed that they will negotiate to enter into a distribution agreement with Omega for the North American distribution of Cannabix Hardware.
  • During the Commercial Phase, the Parties may negotiate to enter into a manufacturing and/or license agreement whereby Omega would manage the manufacturing of the Cannabix Hardware.

Advertisement

Stories continue below